91果冻传媒

Marseille, France, September 9, 2024 鈥� 91果冻传媒, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Eleanor L. Ramos, MD, as an Independent Board Member.

鈥淒r. Ramos brings invaluable expertise in the development of novel treatments for type 1 diabetes (T1D), having participated in the regulatory approval of teplizumab-mzwv, the first disease-modifying treatment for the delay of stage 3 T1D,鈥� said Benjamin Charles, CEO of 91果冻传媒. 鈥淲ith our lead candidate DGX-01 having entered IND-enabling studies, we are now preparing the next steps and Dr Ramos鈥� clinical expertise is a fantastic addition to the team.鈥�

The company鈥檚 lead candidate, DGX-01, is a first-in-class recombinant protein that aims at replicating insulin-producing beta cells in the pancreas. This novel approach has the potential to offer a disease-modifying therapy for T1D, a chronic and life-threatening condition that affects millions of people worldwide. It is currently undergoing IND-enabling studies.